Literature DB >> 12230922

Patient preferences regarding antiretroviral therapy.

Loren G Miller1, Heather B Huffman, Beverly A Weidmer, Ron D Hays.   

Abstract

Antiretroviral medications for HIV infection can be combined into dozens of recommended regimens. However, little is known about patient preferences regarding antiretroviral therapy. We assessed the impact of clinician-mutable adherence barriers by conducting four patient focus groups (two English and two Spanish) consisting of 30 patients that focused discussion on antiretroviral treatment preferences. We also surveyed antiretroviral treatment preference from 31 subjects using the method of paired comparisons in which subjects indicated their preferences of regimen potency, pill burden, inconvenience, and side-effects using a 10-point rating scale. We found that most patients would tolerate severe side-effects, inconvenience, and large pill burden to have a potent antiretroviral regimen. In our population, patients generally preferred regimens with fewer side-effects to those with less inconvenience. Pill burden was of least importance among the domains studied. These preferences should be considered when selecting a regimen and developing interventions to improve antiretroviral adherence and patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230922     DOI: 10.1258/09564620260216281

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  7 in total

Review 1.  How qualitative methods contribute to understanding combination antiretroviral therapy adherence.

Authors:  Andrea Sankar; Carol Golin; Jane M Simoni; Mark Luborsky; Cynthia Pearson
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

Review 2.  Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count.

Authors:  Courtney V Fletcher
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators.

Authors:  Edward J Mills; Jean B Nachega; David R Bangsberg; Sonal Singh; Beth Rachlis; Ping Wu; Kumanan Wilson; Iain Buchan; Christopher J Gill; Curtis Cooper
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

4.  Osteoporosis medication profile preference: results from the PREFER-US study.

Authors:  Thomas W Weiss; Colleen A McHorney
Journal:  Health Expect       Date:  2007-09       Impact factor: 3.377

5.  Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development.

Authors:  I E H Kremer; P J Jongen; S M A A Evers; E L J Hoogervorst; W I M Verhagen; M Hiligsmann
Journal:  BMC Med Inform Decis Mak       Date:  2021-04-09       Impact factor: 2.796

6.  Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.

Authors:  Shannon Schrader; Susan K Chuck; Laurie W Rahn; Paras Parekh; Katherine G Emrich
Journal:  AIDS Res Ther       Date:  2008-09-17       Impact factor: 2.250

7.  Patient preferences for antiretroviral therapy: effectiveness, quality of life, access and novel delivery methods.

Authors:  Ellen F Eaton; Chastity McDavid; Mary Katy Banasiewicz; Michael J Mugavero; Sara J Knight
Journal:  Patient Prefer Adherence       Date:  2017-09-18       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.